Mr. Gabriel Fahel reports

CYBIN ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Cybin Inc. has released the voting results for each of the matters presented at the company's annual and special meeting of shareholders held on Oct. 12, 2023. There were 66 shareholders represented in person or by proxy at the meeting, holding 91,903,025 common shares, representing 39.16 per cent of Cybin's total issued and outstanding common shares as at the record date for the meeting. The voting results for each matter presented at the meeting are set out in this news release.

Acquisition resolution

The acquisition of Small Pharma Inc., by way of a proposed plan of arrangement under the Business Corporations Act (British Columbia), pursuant to the terms and subject to the conditions of the arrangement agreement between Cybin and Small Pharma, dated Aug. 28, 2023, was approved. Voting results are set out in an attached table.

Appointment of auditor

Zeifmans LLP was appointed as the auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out in an attached table.

Number of directors

The special resolution to set the number of directors of Cybin at six was approved by at least two-thirds of the votes casts by the shareholders who voted in respect of the resolution present or represented by proxy at the meeting. Voting results are set out in an attached table.

Election of directors

Each of the nominees for election as a director listed in Cybin's management information circular dated Sept. 13, 2023, was elected as a director of Cybin for the ensuing year or until such director's successor is elected or appointed. Voting results are set out in an attached table.

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

We seek Safe Harbor.